Objective STEAP4 (six-transmembrane epithelial antigen of the prostate 4) is a metalloreductase that has been shown previously to protect cells from inflammatory damage. Genetic variants in STEAP4 have been associated with numerous metabolic disorders related to obesity, including putative defects in the acute insulin response to glucose in type 2 diabetes.
Purpose We examined whether obesity and/or type 2 diabetes altered STEAP4 expression in human pancreatic islets. Methods Human islets were isolated from deceased donors at two medical centers and processed for quantitative polymerase chain reaction. Organ donors were selected by status as nondiabetic or having type 2 diabetes. Site 1 (Edmonton): N = 13 type 2 diabetes donors (7M, 6F), N = 20 non-diabetic donors (7M, 13F). Site 2 (Virginia): N = 6 type 2 diabetes donors (6F), N = 6 non-diabetic donors (3M, 3F). Results STEAP4 showed reduced islet expression with increasing body mass index among all donors (P < 0.10) and non-diabetic donors (P < 0.05) from Site 1; STEAP4 showed reduced islet expression among type 2 diabetes donors with increasing hemoglobin A1c. Islet STEAP4 expression was also marginally higher in female donors (P < 0.10). Among type 2 diabetes donors from Site 2, islet insulin expression was reduced, STEAP4 expression was increased, and white blood cell counts were increased compared to non-diabetic donors. Islets from non-diabetic donors that were exposed overnight to 5 ng/ml IL-1β displayed increased STEAP4 expression, consistent with STEAP4 upregulation by inflammatory signaling. Conclusions These findings suggest that increased STEAP4 mRNA expression is associated with inflammatory stimuli, whereas lower STEAP4 expression is associated with obesity in human islets. Given its putative protective role, downregulation of STEAP4 by chronic obesity suggests a mechanism for reduced islet protection against cellular damage.
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The intersection between low-grade inflammation and betacell dysfunction has gained increased interest in recent years as a key factor in the pathophysiology of type 2 diabetes (T2D). It has previously been shown that islets from T2D donors demonstrate inflammatory changes at the histological level [1] [2] [3] [4] , and an inflammatory milieu heightens the risk for T2D development in prospective clinical studies [5] . A potential player in this intersection is sixtransmembrane epithelial antigen of the prostate 4 (STEAP4; also called STAMP2 [6] or TIARP [7] ). A number of genome-wide association studies suggest that STEAP4 is involved with numerous disorders related to obesity and metabolism including insulin resistance [8, 9] , metabolic syndrome [10, 11] , and insulin levels [12, 13] . Beyond its known role as a metalloreductase [14] , studies have shown that STEAP4 plays an anti-inflammatory or protective role from cellular damage in adipocytes [9, 15] , mesangial cells [16] , hepatocytes [17] [18] [19] , and synoviocytes [20] . In studies of mice, the STEAP4-/-phenotype includes the spontaneous development of obesity, insulin resistance, and eventual hyperglycemia [21] , as well as signs of atherosclerosis [22] , also suggesting a protective role for the protein.
The limited data in humans generated thus far have been conflicting. Human abdominal subcutaneous and omental white adipose tissue collected from insulin-resistant individuals was associated with increased STEAP4 levels in a pair of studies [23, 24] . By contrast, several similar studies have demonstrated decreased STEAP4 expression in visceral adipose tissue with increased adiposity or body mass index (BMI) [25] [26] [27] [28] .
Our laboratory has recently demonstrated that STEAP4 is expressed in rodent islets and strongly upregulated in response to low-grade inflammation [13] . Further, single nucleotide polymorphisms in STEAP4 have been associated with differences in acute insulin response to glucose (AIRg) in a human population prone to obesity and T2D [13] , suggesting a role for STEAP4 in pancreatic islet function in obesity and/or T2D. In the present study, we compared STEAP4 expression in human islets collected from T2D donors and non-diabetic controls from two different sites to determine what factors are associated with differences in STEAP4 expression at the islet level.
Materials and methods
Human islet isolations at University of Alberta (Edmonton) Human islets were isolated from donor organs at the Alberta Diabetes Institute IsletCore (www.bcell.org/IsletCore.html) or the Clinical Islet Laboratory at the University of Alberta as described [29] and cultured as described [30] . Information on donor age, BMI, sex, and hemoglobin A1c (HbA1c) were provided.
Human islet isolation at University of Virginia (Virginia)
Human pancreatic islets were isolated at the University of Virginia cell processing facility. Under good manufacturing practice (GMP) conditions, pancreata were cleaned of extraneous tissue; inflated with Liberase MTF collagenase and digested using the Ricordi method. Digestate was washed and pelleted for purification. Purification was performed using a COBE 2991 cell processor with a continuous Biocoll gradient. Purified pancreatic islets were cultured in CMRL media supplemented with 10% human albumin, nicotinomide and glutathione. Cultured islets were considered high purity if purity was 85% or above.
Select medical data were available for human islets sourced from University of Virginia consisting of basic demographic information and results of laboratory studies performed during hospital admission prior to death. The following serum studies were analyzed across the donor set: sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, calcium, albumin, international standardized ratio, lipase, white blood count, and hemoglobin. Several sets of values were available for each donor, as multiple iterations had been performed during hospitalization. The maximum, minimum, average, and final values of each study category were compiled and compared by scatter plot with islet STEAP4 expression values.
RNA isolation and qPCR of human islet samples
For the Edmonton samples, islets were hand-picked to >99% purity and RNA was extracted using TRIzol Reagent (ThermoFisher Scientific, Burlington, ON. Canada) and reverse transcription performed using 5× All-in-One RT Master Mix (Applied Biological Materials Inc, Richmond, BC, Canada). qPCR was performed on a 7900HT Fast RealTime polymerase chain reaction System using Fast SYBR Green Master Mix (ThermoFisher Scientific) and primers listed below.
For the Virginia samples, RNA isolations were performed using an AllPrep DNA/RNA/Protein mini Kit from Qiagen GmbH (Hilden, Germany) and reverse transcription of 0.25-1 µg RNA using a High Capacity cDNA kit (Life Technologies). qPCR was performed using iQ SYBR green SuperMix (Bio-Rad, Hercules, CA, USA) on an iCycler (MyiQ Optical Module) Bio-Rad system. mRNA expression was quantified based on the hypoxanthine phosphoribosyltransferase 1 (HPRT1) house-keeping gene, using the Relative Expression Software Tool [31] . Outliers were removed based on their relation to the interquartile range (IQR). Specifically, gene expression less than (First Quartile (Q1) -1.5*IQR) or greater than (Third Quartile (Q3) + 1.5*IQR) were considered outliers. The following key primer sets were used: for hHPRT1, forward (5′-ATGGA-CAGGACTGAACGTCT-3′) and reverse (5′-TCCAGCAGGTCAGCAAAGAA-3′); for insulin, forward (5′-TGCGGGGAACGAGGCTTCTTCTA-3′) and reverse (5′-AGGGACCCCTCCAGGGCCAAG-3′); for STEAP4, forward (5′-GCGCCTCTCCCTCAGTTATG-3′) and reverse (5′-GGTCTTCTGGGGGTTTCGAC-3′). A full list of primers is included as Supplemental Table S1 .
Note that STEAP4 values were normalized to HPRT1 gene for both the Edmonton and Virginia data sets. STEAP4 expression patterns in the Edmonton group were also normalized to 18 s, but similar results were observed with either control. For the data reported here, STEAP4 expression was normalized to HPRT1 unless otherwise stated.
Statistics
Correlations between STEAP4 and chart data were made by Pearson correlation. GraphPad Prism software was used to determine P-values for linear regression analysis. A twotailed t test was used for all other comparisons. P-values <0.05 were considered significant.
Results

Site-related differences in STEAP4 expression
The same primers were used at both islet isolation sites to measure STEAP4 mRNA and HPRT1 control mRNA, however, STEAP4 expression among all donors from the Edmonton site was 4.1 ± 0.2-fold over the HPRT1 values versus 2.1 ± 0.4 for the Virginia site (P = 0.0003). Due to this disparity between data sets, we analyzed the data from each site separately. We have also provided the results of analysis using the combined data sets from both sites in Supplemental Table S2 for comparison.
Donor characteristics from University of Alberta (Edmonton)
We examined islets from n = 20 non-T2D donors and n = 13 T2D donors isolated at the University of Alberta (Edmonton). As shown in Table 1 , no differences in age or BMI among T2D vs non-T2D donors were observed. Glycosylated hemoglobin (HbA1c) was significantly higher among donors with T2D.
T2D donors tended to be older than non-T2D donors, but differences did not reach statistical significance. Scatter plot analysis across all ages produced a correlation coefficient of R 2 = 0.002 with STEAP4 expression (not significant). In addition, among donors 60 years of age and over (the highest quartile), STEAP4 expression levels were 4.0 ± 0.6-fold of the HPRT1 house-keeping gene, whereas STEAP4 levels for donors 40 years of age or under (lowest quartile) were 3.8 ± 0.5 (P = 0.72). Thus, STEAP4 values do not appear to differ with age.
Decreased STEAP4 expression is associated with increased BMI (Edmonton)
Initial observations showed no statistically significant differences between islets isolated from non-T2D donors (4.1 ± 0.3, n = 20) and T2D donors (4.0 ± 0.4, n = 13). We next analyzed BMI as a categorical variable and grouped T2D and non-T2D donors as lean (BMI ≤ 25), overweight (25 > BMI ≤ 30), or obese (BMI > 30). In this analysis among all donors from Site 1, STEAP4 expression was marginally reduced (P < 0.10) in obese compared to lean donors (Fig. 1a) . This relationship was more apparent among non-T2D donors, where islets from obese donors had significantly reduced STEAP4 expression compared to lean and overweight donors (Fig. 1b) . These findings are consistent with several studies showing that STEAP4 levels in adipose tissue decrease with increasing adiposity [25] [26] [27] . Surprisingly, no significant changes in STEAP4 expression were observed among T2D islet donors betwteen lean, overweight, and obese categories, as shown in Fig. 1c . When evaluated as a continuous variable, BMI was significantly correlated with reduced STEAP4 levels for all donors combined (Fig. 1d) , for non-T2D donors (Fig. 1e) , but not for T2D donors (Fig. 1f) .
STEAP4 expression is reduced with increasing HbA1C in T2D donors (Edmonton)
We next examined the relationship between STEAP4 expression and HbA1c. As shown in Fig. 2a , HbA1c was elevated among T2D donors (see also Table 1 ), but there were no overall differences in STEAP4 expression levels between T2D and non-T2D donors. When examined by scatter plot, STEAP4 showed no relationship with HbA1c among islets from all donors (P = 0.17) or among non-T2D donors (Fig. 2b) . In contrast, STEAP4 was negatively correlated with HbA1C (P = 0.01) among T2D donors, as shown in Fig. 2c .
STEAP4 expression is higher in female donors compared to male donors
We also examined STEAP4 expression for possible differences between male and female donors. Combining both T2D and non-T2D donor islets in the Edmonton group, the fold change for STEAP4 expression over the housekeeping gene HPRT1 in islets from female donors (4.4 ± 0.3, n = 19) was marginally higher than in islets from male donors (3.6 ± 0.4, n = 14, P < 0.10). STEAP4 levels were slightly higher in islets from female donors compared to male donors for both non-T2D and T2D subsets, but these differences were not significant. Higher STEAP4 levels were also observed in islets from female donors in the Virginia group (Female: 2.6 ± 0.5, n = 8 vs. Male: 0.7 ± 0.2, n = 3, P < 0.01, see also Table 2 ) and when both data sets from Site 1 and Site 2 were combined (P < 0.10, see Supplemental Table S2 ). STEAP4 expression levels thus appear to be consistently higher in islets from females compared to males, although the significant of these differences is marginal (P-values of 0.05-0.10 in most comparisons).
Donor characteristics from the University of Virginia and STEAP4 correlations (Virginia)
Studies were also performed on islet STEAP4 expression levels with a donor base from Virginia. Clinical chart data from hospitalizations prior to death were available for most tissue donors from Virginia. A summary of key demographic information is shown in (Table 2) . Tissue samples were obtained from a total of N = 7 females and N = 3 males. Notably, all five donors from the T2D group were female. The cause of death for the majority of donors was cerebrovascular accident (CVA). Anoxia, central nervous system (CNS) tumor, and cervical fracture accounted for the deaths of the three other donors, respectively. There were no significant differences in age or BMI between the two groups.
Analysis of chart data yielded a number of significant differences. STEAP4 expression levels correlated strongly to maximum serum sodium (R 2 = 0.6279, P = 0.006) and maximum serum chloride (R 2 = 0.704, P = 0.002) as shown in Fig. 3a and b. "Maximum" refers to the highest value recorded among multiple measures while in hospital. A borderline significant correlation to STEAP4 was also observed for mean sodium (R 2 = 0.3801, P = 0.06) and mean chloride (R 2 = 0.3794, P = 0.06). This correlation may indicate STEAP4 upregulation related to the acute patient condition in hospital.
Mean white blood cell (WBC) counts differed markedly between T2D and non-T2D donor populations, as shown in Table 2 . Maximum WBC count (P = 0.004, Fig. 3c ) and last WBC (P = 0.004) also differed between the two groups, with higher counts found in the T2D group.
STEAP4 is upregulated by exposure to interleukin 1-beta (Virginia)
Since STEAP4 is highly sensitive to cytokine-induced expression and inflammatory signaling [7, 13, 32] , we examined whether exposure to proinflammatory conditions could directly increase STEAP4 expression in human islets. We exposed islets from three non-T2D donors to 5 ng/ml IL-1β + 25 mM glucose conditions overnight and then collected mRNA to measure STEAP4 expression levels. As shown in Fig. 3d , STEAP4 expression was markedly upregulated compared to untreated controls. In contrast to chronic obesity or hyperglycemia downregulating STEAP4 expression, these data suggest an increase in inflammation or immune response may be responsible for the increased STEAP4 expression. Note that 25 mM glucose exposure could be regarded as a hyperglycemic trigger of STEAP4 in addition to IL-1β. We showed in rodent islets, however, that chronic high glucose exposure has little impact on STEAP4 levels [13] , especially compared to cytokine effects.
STEAP4 gene expression in comparison to key markers of islet function (Virginia)
Expression levels of the following known pancreatic islet genes were quantified in relation to the HPRT1 housekeeping gene: STEAP4, genes related to secretory hormones (insulin, glucagon), genes related to maintenance of normal islet function (GLUT1, GLUT2, PDX1, NKX6-1, and KCNJ11), genes related to insulin signaling pathways (GLP1R, INSR, IRS2, and IGF1R), and genes related to metabolism (CITED2, ACC1, ACC2, FASN, and SCD1). The fold change in mRNA expression between donors with T2D and donors without T2D are shown in Fig. 4a . Among all 17 genes examined, only insulin (P = 0.04) and STEAP4 (P = 0.03) showed significant differences between donor populations. Islets from donors with T2D expressed significantly lower levels of insulin (expected for individuals with T2D) and significantly higher levels of STEAP4 compared to islets from non-diabetic donors. However, there was a strong relationship between STEAP4 expression and insulin expression (R 2 = 0.90, P = 0.01, n = 5) in the T2D population, with low levels of insulin correlated with low levels of STEAP4 expression in islets. Since loss of insulin is related to hyperglycemia, the reduced STEAP4 levels with low insulin is consistent with the lower STEAP4 with increased HbA1c observed in the Edmonton data. Notably, one outlier from the T2D group was included in Table 2 but excluded from all analysis due to exceptionally high STEAP4 expression (fold change of 26.61); the high expression did not appear to correlate with unusual values in any other measured parameter.
Discussion
This is the first study to show that STEAP4 is expressed in the human pancreatic islet. Our data suggest that multiple regulatory factors contribute to increased or decreased STEAP4 expression, as depicted in Fig. 4b . Known and putative upregulating factors include pro-inflammatory cytokines [7, 13, 32, 33] , nutrient intake [21] , and acute cellular stress [13, 21] . Downregulating factors of STEAP4 include obesity [25] [26] [27] [28] , HbA1c/diabetic condition [26] , and chronic inflammation.
We discuss below how these putative competing regulatory factors may impact islet STEAP4 expression.
STEAP4 expression in obesity
The relationship between STEAP4 and obesity is not entirely clear due to conflicting findings in the literature. A pair of studies showed that STEAP4 levels in adipocytes and white adipose tissue were increased in obesity [23, 24] , whereas other studies showed that STEAP4 was downregulated in obese people [25] [26] [27] [28] . In yet another study, STEAP4 gene expression in both fat and muscle was reduced among the most insulin resistant individuals independent of BMI [34] .
With regard to islets, we showed a clear and significant decrease in STEAP4 with increasing BMI, especially among non-T2D donors (Edmonton, Site 1). T2D donors in the Edmonton group were skewed toward higher BMI with only N = 2 lean donors (BMI < 25), thus potentially masking a relationship. STEAP4 levels in T2D donors were decreased with increasing HbA1c, suggesting an inverse relationship between STEAP4 expression and severity of hyperglycemia. For the Virginia data (Site 2), determining a relationship between STEAP4 expression and BMI was not statistically feasible due to the smaller sample size and relatively tight distribution of BMI values (10 of 12 donors were non-obese, (<30 BMI)). Even with these limitations, trend lines pointed to an inverse relationship between STEAP4 expression and BMI for both T2D and non-T2D donors, thus supporting the Edmonton findings.
STEAP4 expression and acute vs. chronic inflammation
Because obesity is associated with chronic low-grade inflammation and therefore elevated cytokine levels, reduced STEAP4 expression with increased obesity seems counterintuitive to previous research showing upregulation of STEAP4 in the presence of cytokines [7, 13, 32, 33] . Our data show that direct overnight exposure to pro-inflammatory cytokines (5 ng/ml IL-1β) increases expression of STEAP4 in human islets from non-T2D donors, supporting previous studies [7, 13, 32, 33] . Note that glucose was also elevated for the overnight cytokine treatment, but high glucose alone does not appear to increase STEAP4 expression in islets [13] . We also showed that T2D donors from the Virginia cohort had increased WBC counts compared to non-T2D controls, which may be indicative of an acute immune response. Sodium and chloride values were also associated with increased STEAP4 expression, indicating a possible relationship to dehyration and/or inflammation. Overall, these data are consistent with an increase in STEAP4 in acute inflammatory circumstances. The reduced STEAP4 levels with elevated BMI may be due to chronic aspects of obesity, such as chronic low-grade inflammation, causing STEAP4 downregulation. Of interest, STEAP4 levels are lower in circulating macrophages of women with metabolic syndrome (MetS) compared to controls [35] , suggesting downregulation of STEAP4 in inflammatory cells in chronic metabolic diseases. Thus, differences in STEAP4 expression may be due, at least in part, to differences between chronic and acute inflammation with regard to cytokine dose, duration, and milieu [36] .
Male vs. Female
Islets from female donors in the Edmonton cohort generally showed higher STEAP4 expression compared to male donors. All Virginia T2D donors were female, while the non-T2D donors had equal male and female inclusion (n = 3 each). It should be noted that the three lowest STEAP4 values among all n = 11 donors from the Virginia cohort were all the male samples (See Table 2 ). Therefore, sex differences could explain, in part, why the STEAP4 expression in the Virginia T2D donors was higher than in non-T2D donors.
The underlying physiological reason for differences in islet STEAP4 expression between sexes is not known. It is significant to note that women with MetS show down regulation in STEAP4 expression compared to non-MetS, (N = 4) . d STEAP4 expression in islets isolated from N = 3 donors treated overnight (24 h) with 5 ng/ml interleukin1beta in 25 mM glucose or untreated. *P < 0.05, **P < 0.01 while men show no significant differences in expression between those with MetS vs. those without [35] . Other regulating factors to consider are hormones such as testosterone, which upregulates the expression of STEAP4 [37] .
Additional considerations and limitations
The differences in STEAP4 expression between the Edmonton site and Virginia site warrant additional discussion. A limitation of our study is that donor data sets were not equivalent. Thus, analysis and data presentation for each site were performed separately and were difficult to combine. For example, WBC count was known for Virginia, but not Edmonton, thus complicating analysis of the role of inflammation in both cohorts. The Virginia cohort did not provide sufficient statistical power to account for sex, BMI, or hemoglobin A1c. In addition, therapeutic interventions between donors groups, disease management of donors, medical status at death, and even differences in health care systems between countries [38] could contribute to the observed differences in STEAP4 expression. What we have attempted to do is to identify factors for which we could find a strong correlation with STEAP4 expression, while acknowledging other potential confounding factors.
The islet isolation procedures between sites also differed, resulting in potential differences in islet viability and function. Importantly, islets from Edmonton were handpicked >99% purity, whereas the Virginia islets were purified to >85%, resulting in different levels of acinar tissue in the samples that could impact gene expression levels. Note that the islets themselves are composed predominantly of insulin-secreting beta-cells, glucagon-secreting alpha-cells, and somatostatin-secreting delta-cells [39, 40] , but the proportions of these cell types may differ from donor to donor, which could also impact expression. While differences in islet purity may contribute to differences in results between sites, we observed more similarities than differences when comparable between sites, as discussed above.
Conclusions
Several studies suggest that STEAP4 plays a protective role in the face of inflammatory stress in models of metabolic disorders [9, 21, 22, 41, 42] . Thus, if obesity results in reduced STEAP4 expression levels, this may depress a normal compensatory responses to cellular stress. Moreover, reduced STEAP4 could directly impact insulin secretory function. Genetic variants in STEAP4 have been associated differences in the AIRg (also called first phase) in a diabetes-prone population [13] . Our overall findings suggest that STEAP4 expression is downregulated by factors such as chronic obesity (BMI) and hyperglycemia (HbA1c) but upregulated by acute inflammation or cytokine exposure at the level of the pancreatic islet (see Fig. 4b ). These findings point to complex regulatory inputs to STEAP4, a protein that is increasingly associated with a protective role in metabolic disorders. Continued work toward elucidating what regulates STEAP4 and what role STEAP4 plays in metabolic disorders is warranted.
